Spruce Biosciences, Inc.
SPRB
$0.1298
-$0.0101-7.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 697.00K | 602.00K | 1.61M | 2.00M | 2.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 697.00K | 602.00K | 1.61M | 2.00M | 2.89M |
| Cost of Revenue | 21.46M | 6.55M | 8.09M | 10.32M | 11.10M |
| Gross Profit | -20.76M | -5.95M | -6.48M | -8.32M | -8.21M |
| SG&A Expenses | 3.31M | 3.46M | 3.56M | 4.32M | 2.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.77M | 10.01M | 11.65M | 14.64M | 14.05M |
| Operating Income | -24.07M | -9.41M | -10.04M | -12.63M | -11.16M |
| Income Before Tax | -23.56M | -8.67M | -9.18M | -11.63M | -9.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.56M | -8.67M | -9.18M | -11.63M | -9.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.56M | -8.67M | -9.18M | -11.63M | -9.95M |
| EBIT | -24.07M | -9.41M | -10.04M | -12.63M | -11.16M |
| EBITDA | -24.07M | -9.40M | -10.02M | -12.62M | -11.15M |
| EPS Basic | -0.57 | -0.21 | -0.22 | -0.28 | -0.24 |
| Normalized Basic EPS | -0.35 | -0.13 | -0.14 | -0.18 | -0.15 |
| EPS Diluted | -0.57 | -0.21 | -0.22 | -0.28 | -0.24 |
| Normalized Diluted EPS | -0.35 | -0.13 | -0.14 | -0.18 | -0.15 |
| Average Basic Shares Outstanding | 41.50M | 41.30M | 41.16M | 41.10M | 40.79M |
| Average Diluted Shares Outstanding | 41.50M | 41.30M | 41.16M | 41.10M | 40.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |